Aduro Biotech, Inc. (ADRO)
(Delayed Data from NSDQ)
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
by Zacks Equity Research
Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered
by Zacks Equity Research
Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported second-quarter 2017 results wherein earnings beat expectations but sales missed the same.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
by Zacks Equity Research
VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.
Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top
by Zacks Equity Research
Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.
AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study
by Zacks Equity Research
AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.
Mirati Therapeutics (MRTX) Rises: Stock Moves 11.5% Higher
by Zacks Equity Research
Mirati Therapeutics, Inc. (MRTX) shares rose over 11% in the last trading session.
Alexion Reportedly Being Investigated by HHS, Shares Slip
by Zacks Equity Research
Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG).
Verastem (VSTM) Shows Strength: Stock Adds 42% in Session
by Zacks Equity Research
Verastem, Inc. (VSTM) shares jumped almost 42% in the last trading session.
Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up
by Zacks Equity Research
Celsion Corp. (CLSN) shares rose after the company has announced completion of enrolment in a phase Ib study, evaluating its immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer.
Geron Stock Up Almost 40% So Far This Year After '16 Decline
by Zacks Equity Research
Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.
Aduro Starts Phase II Combo Study with CRS-207 & Keytruda
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).
Can Aduro BioTech (ADRO) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) is an immunotherapy company that could be an interesting play for investors.
Aduro's Drug Gets Clearance by the FDA for Solid Tumors
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) announced that the FDA has cleared the Investigational New Drug application (IND) for its pipeline candidate ADU-S100 (MIW815).
Why Is Aduro (ADRO) Down 3.6% Since the Last Earnings Report?
by Zacks Equity Research
Aduro (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
Aduro (ADRO) Inks License Agreement with Stanford University
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology.